Similarly, different transcriptional subtypes referred to thyroid differentiation (TD) and to MAPK pathway output have been established, with BRAFV600E and BRAF-like tumor displaying loss of TD and higher activation of the MAPK pathway, which could explain the worse prognosis in BRAFV600E- compared with RAS-mutated patients (4). This evidence concerns the gene BRAF and neoplasm.